close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

Kodu・Aktsiate loetelu・AbCellera Biologics Inc
Search

AbCellera Biologics Inc

Avatud

SektorTervishoid

3.44 7.17

Tugev "osta" hinnang

Hinna uuendus 26. veebr 2026, 16:01 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.13

Max

3.34

Põhinäitajad

By Trading Economics

Sissetulek

-22M

-57M

Müük

-8.1M

9M

Kasumimarginaal

-637.845

Töötajad

596

EBITDA

-1.4M

-40M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+117.39% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-698M

907M

Eelmine avamishind

-3.73

Eelmine sulgemishind

3.44

Uudiste sentiment

By Acuity

76%

24%

325 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.99 / 2.635 Toetus ja vastupanu

AbCellera Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. veebr 2026, 23:25 UTC

Kuumad aktsiad

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

DJ

Loe

25. veebr 2026, 23:15 UTC

Tulu

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

DJ

Loe

25. veebr 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

DJ

Loe

25. veebr 2026, 23:47 UTC

Tulu

Ferrovial 4Q Net EUR197M >FER.MC

DJ

Loe

25. veebr 2026, 23:45 UTC

Tulu

Ferrovial 4Q Rev EUR2.72B >FER.MC

DJ

Loe

25. veebr 2026, 23:42 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

DJ

Loe

25. veebr 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Company's Business Operations Remain Normal >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY EPS CNY47.67 >TCOM

DJ

Loe

25. veebr 2026, 23:06 UTC

Tulu

Correction to Nvidia Fourth Quarter Results Article -- WSJ

DJ

Loe

25. veebr 2026, 23:01 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

DJ

Loe

25. veebr 2026, 23:00 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

DJ

Loe

25. veebr 2026, 23:00 UTC

Market Talk
Tulu

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

DJ

Loe

25. veebr 2026, 22:56 UTC

Market Talk
Tulu

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

DJ

Loe

25. veebr 2026, 22:43 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

DJ

Loe

25. veebr 2026, 22:40 UTC

Market Talk
Tulu

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

DJ

Loe

25. veebr 2026, 22:40 UTC

Tulu

Karoon Energy Says Search for New CFO Well Advanced

DJ

Loe

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says CFO Ray Church to Leave Company

DJ

Loe

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

DJ

Loe

25. veebr 2026, 22:38 UTC

Tulu

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

AbCellera Biologics Inc Prognoos

Hinnasiht

By TipRanks

117.39% tõus

12 kuu keskmine prognoos

Keskmine 7 USD  117.39%

Kõrge 7 USD

Madal 7 USD

Põhineb 4 Wall Streeti analüütiku instrumendi AbCellera Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Põhineb 4 analüütiku instrumendi AbCellera Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.99 / 2.635Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Pikk perspektiiv

Weak Bearish Evidence

Bearish events outweigh bullish events.

Sentiment

By Acuity

325 / 351 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,014.52

↓-3.15%

JNJ

Johnson and Johnson

243.43

↓-0.55%

ABBV

AbbVie Inc

224.55

↓-3.14%

NVS

Novartis AG

165.62

↓-1.16%

MRK

Merck & Co Inc.

120.01

↓-3.14%
help-icon Live chat